Across more than three decades in medicine, cancer biology, global health, and biopharmaceutical R&D, Dr. Oscar L. Kashala has worked where scientific discovery meets clinical development and patient care. That trajectory has shaped a perspective relevant to oncology strategy: future R&D will depend on integrating biology, populations, institutions, and geographies into a globally relevant system.
From Molecular Biology to Global Drug Development
Kashala’s early career evolved from internal medicine and clinical pathology in the Democratic Republic of Congo and Switzerland into oncology, cancer biology, immunology, and virology. His training included the Universities of Geneva and Lausanne, the Swiss Institute for Experimental Cancer Research, the WHO Immunology Training and Research Center in Epalinges, and later Harvard and MIT—an interdisciplinary foundation for his approach to translational medicine and global drug development.
His biopharmaceutical career began at Cambridge Biotech Corporation, later Aquila Biopharmaceuticals, where his work included HIV vaccine development and an early effort to incorporate African HIV-strain diversity into vaccine research. With support from U.S. government agencies, the World Health Organization, and industry collaborators, he initiated what contemporaneous company materials described as the first HIV-1 vaccine studies based on strains prevalent in Africa. At Millennium Pharmaceuticals, he contributed to the clinical and safety development of bortezomib (VELCADE®) and led international programs across multiple solid tumors. At EMD Serono/Merck KGaA, his responsibilities broadened to U.S. oncology development leadership, portfolio and registrational strategy, and international collaborations, including cancer-vaccine programs and randomized Phase III development of a MUC1-targeted therapeutic cancer vaccine. At Affimed, he helped build U.S. clinical and translational infrastructure around its innate-cell-engager bispecific-antibody platform; subsequent work with Molecular Partners expanded his experience in targeted biologics. Today at Therabene, these experiences converge around an integrated model linking mechanism, biomarkers, targeted therapeutics, translational science, regulatory strategy, and global clinical development.
Where Pharma R&D Is Going
The importance of that progression lies less in the sequence of positions than in the development philosophy it produced. Oncology R&D can no longer function as sequential handoffs. Target biology, translational models, patient selection, companion diagnostics, safety, regulatory strategy, and implementation increasingly need to be designed as one system.
Therabene’s work on cyclin-dependent kinase 9 (CDK9) illustrates this principle. CDK9 sustains transcriptional addiction through short-lived oncogenic proteins such as MYC and MCL-1, while targeted protein degradation may move beyond kinase inhibition by eliminating catalytic and non-catalytic target functions. Kashala sees AI, multi-omics, spatial biology, biomarkers, and targeted protein degradation as tools to improve R&D productivity when paired with biologically representative evidence.
Ancestry-Awareness: A Scientific Foundation for Precision Medicine
A central element of Kashala’s recent thought leadership is ancestry-aware drug development. At the 15th Annual Clinical Trials in Oncology East Coast Conference in Boston on June 30, 2026, he challenged the assumption that oncology evidence is fully generalizable when pivotal trials inadequately represent the biological diversity of patients expected to receive the medicines.
| “The current oncology evidence-generation system can no longer claim full biological validity when pivotal evidence is generated in populations that do not represent the global biology of cancer patients. Ancestry-aware trial design is a scientific upgrade to precision oncology, a regulatory necessity, and a business advantage.” |
Ancestry-awareness is not a return to racial classification. Race is not biology, and ancestry is not destiny. Rather, it calls for study of measurable host determinants of drug response, including pharmacogenomic variation, HLA and immunogenomic diversity, microbiome composition, infection history, epigenetic regulation, environmental exposures, and population genomic structure. These factors can influence efficacy, toxicity, biomarker performance, and resistance.
Africa is central to this argument. Modern Homo sapiens emerged in Africa roughly 200,000–300,000 years ago, and subsequent population bottlenecks left African populations with the greatest breadth of human genomic diversity. That diversity is a powerful resource for discovering disease mechanisms, pharmacogenomic variants, therapeutic targets, biomarkers, and determinants of drug response. Africa is therefore not simply a geography of unmet need, but an engine of biomedical discovery with global implications.
From Global Collaboration to Research Infrastructure
Earlier in his career, Kashala served as National Director of the planned National Cancer Center of the Democratic Republic of Congo, then Zaire—a center that has yet to be built. The experience reinforced the challenge of building durable cancer-care and research infrastructure in resource-constrained settings.
Today, that institutional question is being approached through collaboration with Kwame Nkrumah University of Science and Technology in Ghana, Afrigentech Company Ltd., Therabene, and prospective partners across Africa, the United States, and other regions. The vision for a regional cancer center and pharmaceutical R&D hub extends beyond care to translational research, molecular diagnostics, biobanking, clinical trials, education, pharmaceutical development, and local manufacturing. Countries, in this model, become co-creators of knowledge rather than trial sites.
Kashala’s participation in the 21st Clinical Trial Strategic Summit in Boston in April 2026, including a fireside discussion on bespoke therapy and the FDA’s evolving approach to individualized treatment in fibrolamellar hepatocellular carcinoma, reflects another principle: regulatory science must evolve alongside precise therapies while preserving rigor.
A New Standard for Better Science, Better Business, and Better Health
Together, these ideas define an outlook for oncology R&D: global in evidence generation, ancestry-aware in biological design, and translational from discovery through implementation. For healthcare leaders, representative evidence can strengthen biomarker performance, reduce development risk, support global regulatory submissions, and improve health-system readiness.
Kashala’s perspective is that organizations best positioned for the next era will connect molecular innovation with population biology and international capability from the beginning. Precision oncology will depend not only on discovering better molecules, but on understanding whom they are for, why they work, how effects differ across populations, and how innovation reaches patients worldwide.
ABOUT THE AUTHOR
Oscar L. Kashala, MD, PhD, DSc, is Chief Medical Officer and Executive Vice President, Global Clinical Development at Therabene, Inc.